{
    "root": "3591b831-319a-efa5-e063-6294a90ad3fe",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin",
    "value": "20250513",
    "ingredients": [
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        }
    ],
    "indications": "adults pediatric patients upper respiratory tract infections ear , nose , throat amoxicillin indicated treatment infections due susceptible ( β-lactamase–negative ) isolates streptococcusspecies . ( α- β-hemolytic isolates ) , streptococcus pneumoniae , staphylococcus spp . , haemophilus influenzae . infections genitourinary tract amoxicillin indicated treatment infections due susceptible ( β-lactamase–negative ) isolates escherichia coli , proteus mirabilis , enterococcus faecalis . infections skin skin structure amoxicillin indicated treatment infections due susceptible ( β-lactamase–negative ) isolates streptococcus spp . ( α- β-hemolytic isolates ) , staphylococcus spp . , e. coli . infections lower respiratory tract amoxicillin indicated treatment infections due susceptible ( β-lactamase–negative ) isolates streptococcus spp . ( α- β-hemolytic isolates ) , s. pneumoniae , staphylococcus spp . , h. influenzae . adult patients helicobacter pyloriinfection duodenal ulcer disease triple therapy helicobacter pylori ( h.pylori ) clarithromycin lansoprazole amoxicillin , combination clarithromycin plus lansoprazole triple therapy , indicated treatment patients h. pyloriinfection duodenal ulcer disease ( active 1-year history duodenal ulcer ) eradicate h. pylori.eradication h. pylorihas shown reduce risk duodenal ulcer recurrence . dual therapy h. pylori lansoprazole amoxicillin , combination lansoprazole delayed-release capsules dual therapy , indicated treatment patients h. pyloriinfection duodenal ulcer disease ( active 1-year history duodenal ulcer ) either allergic intolerant clarithromycin resistance clarithromycin known suspected . ( clarithromycin package insert , microbiology . ) eradication h. pylorihas shown reduce risk duodenal ulcer recurrence . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin antibacterial drugs , amoxicillin used treat infections proven strongly suspected caused bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "adults , 750 to1750 mg/day divided doses every 8 to12 hours . pediatric patients 3 months age , 20 45 mg/kg/day divided doses every 8 to12 hours . refer full prescribing information dosing regimens . ( 2.2 , 2.3 ) upper dose neonates infants aged 3 months younger 30 mg/kg/day divided every 12 hours . ( 2.3 ) dosing h. pylori infection ( adults ) : triple therapy : 1 gram amoxicillin , 500 mg clarithromycin , 30 mg lansoprazole , given twice daily ( every 12 hours ) 14 days . dual therapy : 1 gram amoxicillin 30 mg lansoprazole , given three times daily ( every 8 hours ) 14 days . ( 2.4 ) reduce dose patients severe renal impairment ( gfr greater 30 ml/min ) . ( 2.5 )",
    "warningsAndPrecautions": "amoxicillin capsules , usp , oral , contain 500 mg amoxicillin trihydrate supplied : 500 mg : yellow , opaque , hard gelatin capsules imprinted amox 500 one side gg 849 side . ndc 42708-153-30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles 30 store capsules 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature ] . dispense tight container .",
    "adverseReactions": "amoxicillin contraindicated patients experienced serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin β-lactam antibacterial drugs ( e.g . , penicillins cephalosporins ) .",
    "indications_original": "Adults and Pediatric Patients\n                  \n                  \n                     \n                        Upper Respiratory Tract Infections of the Ear, Nose, and Throat\n                     \n                  \n                  Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n \n  Streptococcusspecies. (α- and β-hemolytic isolates only),\n \n  Streptococcus pneumoniae,\n \n  Staphylococcus spp., or\n \n  Haemophilus influenzae.\n                  \n                  \n                     \n                        Infections of the Genitourinary Tract\n                     \n                  \n                  Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n \n  Escherichia coli, Proteus mirabilis, or Enterococcus faecalis.\n                  \n                  \n                     \n                        Infections of the Skin and Skin Structure\n                     \n                  \n                  Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n \n  Streptococcus spp.(α- and β-hemolytic isolates only),\n \n  Staphylococcus spp., or E. coli.\n                  \n                  \n                     \n                        Infections of the Lower Respiratory Tract\n                     \n                  \n                  Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of\n \n  Streptococcus spp.(α- and β-hemolytic isolates only),\n \n  S. pneumoniae, Staphylococcus spp.,or\n \n  H. influenzae.\n                  \n                  \n                     Adult Patients Only\n                  \n                  \n                     \n                        \n                           Helicobacter pyloriInfection and Duodenal Ulcer Disease\n  \n   \n                     \n                  \n                  \n                     \n                        Triple therapy for Helicobacter pylori (H.pylori) with clarithromycin and lansoprazole\n                     \n                  \n                  Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with\n \n  H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate\n \n  H. pylori.Eradication of\n \n  H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence.\n\n \n                  \n                     \n                        Dual therapy for H. pylori with lansoprazole\n                     \n                  \n                  Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with\n \n  H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer)\n \n  who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected.(See the clarithromycin package insert, MICROBIOLOGY.) Eradication of\n \n  H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence.\n\n \n                  \n                     Usage\n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "In Adults, 750 to1750 mg/day in divided doses every 8 to12 hours. In Pediatric Patients over 3 Months of Age, 20 to 45 mg/kg/day in divided doses every 8 to12 hours. Refer to full prescribing information for specific dosing regimens. ( 2.2 , 2.3 ) The upper dose for neonates and infants aged 3 months or younger is 30 mg/kg/day divided every 12 hours. ( 2.3 ) Dosing for H. pylori Infection (in Adults): Triple therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. ( 2.4 ) Reduce the dose in patients with severe renal impairment (GFR greater than 30 mL/min). ( 2.5 )",
    "warningsAndPrecautions_original": "Amoxicillin Capsules, USP,for oral administration, contain 500 mg amoxicillin as the trihydrate and are supplied as:\n \n                  \n                     500 mg:yellow, opaque, hard gelatin capsules imprinted AMOX 500 on one side and GG 849 on the other side.\n \n                  NDC 42708-153-30.................................................... bottles of 30\n                  \n                  \n                     Store capsules at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].Dispense in a tight container.",
    "adverseReactions_original": "Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins)."
}